BI/Lilly move to shore up Trajenta USP
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim and Eli Lilly are bolstering the position of their third-to-market dipeptidyl peptidase-4 (DPP-4) inhibitor drug linagliptin (Trajenta/Tradjenta) by initiating a new Phase III trial which, if successful, will emphasize the competitive advantage of linagliptin over rival drugs such as Merck & Co's Januvia (sitagliptin) and Bristol-Myers Squibb's Onglyza (saxagliptin), in the treatment of type 2 diabetes.